Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

Basit Öğe Kaydı
dc.authorid0000-0003-3878-988Xen_US
dc.contributor.authorTural, Deniz
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSümbül, Ahmet Taner
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorÖzhan, Nail
dc.contributor.authorAkar, Emre
dc.contributor.authorÇakar, Burcu
dc.contributor.authorKöstek, Osman
dc.contributor.authorEkenel, Meltem
dc.contributor.authorErman, Mustafa
dc.contributor.authorCoşkun, Hasan Şenol
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKeskin, Özge
dc.contributor.authorTürköz, Fatma Paksoy
dc.contributor.authorOruç, Kerem
dc.contributor.authorBayram, Selami
dc.contributor.authorYılmaz, Uğur
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorYıldız, Birol
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorPaksoy, Nail
dc.contributor.authorDirican, Ahmet
dc.contributor.authorErdem, Dilek
dc.contributor.authorSelam, Meltem
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorPaydaş, Semra
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorAtağ, Elif
dc.contributor.authorGüncan, Sabri
dc.contributor.authorÜrün, Yüksel
dc.contributor.authorAlkan, Ali
dc.contributor.authorKaya, Ali Osman
dc.contributor.authorÖzyükseler, Deniz Tataroğlu
dc.contributor.authorTaşkaynatan, Halil
dc.contributor.authorYıldırım, Mustafa
dc.contributor.authorSönmez, Müge
dc.contributor.authorBaşoğlu, Tuğba
dc.contributor.authorGündüz, Şeyda
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2021-12-17T13:01:48Z
dc.date.available2021-12-17T13:01:48Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalıen_US
dc.descriptionWOS:000719424800028
dc.descriptionPMID: 33008789
dc.description.abstractBackground: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma. Design, setting, and participants: Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ. Outcome measurements and statistical analysis: The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were used to calculate median follow-up and estimate PFS and OS. Results and limitations: Data of 115 enrolled patients were analyzed. Most of the patients (92.3%, n = 106) had received chemotherapy regimen only once prior to ATZ. The median follow-up duration was 23.5 mo. The complete response rate, partial response rate, and ORR were 8.7% (n = 10), 20.0% (n = 23), and 28.7% (n = 33), respectively. The median duration of response was 20.4 mo (95% confidence interval [CI], 6.47-28.8). Of the 33 patients who responded to treatment, 60% (n = 20) had an ongoing response at the time of the analysis. PFS and OS with ATZ were 3.8 mo (95% CI, 2.25-5.49) and 9.8 mo (95% CI, 6.7-12.9), respectively. All-cause and any-grade adverse events were observed in 113 (98%) patients. Of the patients, 64% experienced a treatment-related adverse event of any grade and 24 (21.2%) had a grade 3-4 treatment-related adverse event. Limitations of the study included its retrospective design, and determination of treat-ment response based on clinical notes and local radiographic studies. Conclusions: In these real-life data, ATZ was effective and well tolerated in patients with metastatic urothelial carcinoma who have progressed with platinum-based first-line chemotherapy. ATZ is an effective and tolerable treatment for patients with locally advanced or metastatic platinum-resistant urothelial carcinoma in our study, similar to previously reported trials. Patient summary: Atezolizumab is effective and well-tolerated in patients with meta-static urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting. (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.en_US
dc.identifier.citationTural, D., Ölmez, Ö.F., Sümbül, A.T., Artaç, M., Özhan, N., Akar, E. ve diğerleri. (2021). Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences. European Urology Focus, 7(5), 1061-1066.en_US
dc.identifier.doi10.1016/j.euf.2020.09.010
dc.identifier.endpage1066en_US
dc.identifier.issn2405-4569
dc.identifier.issue5en_US
dc.identifier.pmid33008789
dc.identifier.scopus2-s2.0-85091877719
dc.identifier.scopusqualityQ1
dc.identifier.startpage1061en_US
dc.identifier.urihttps://hdl.handle.net/11468/8541
dc.identifier.volume7en_US
dc.identifier.wosWOS:000719424800028
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorUrakçı, Zuhat
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Urology Focus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectUrothelial carcinomaen_US
dc.subjectBladder canceren_US
dc.subjectImmunotherapyen_US
dc.titleAtezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiencesen_US
dc.titleAtezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy Results of Real-life Experiences.pdf
Boyut:
797.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu